Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma
Author:
Funder
Ipsen, Abingdon, UK
Onxeo
Bayer
Ipsen
Publisher
Elsevier BV
Subject
Radiology, Nuclear Medicine and imaging,Oncology,General Medicine
Reference84 articles.
1. Angiogenesis inhibitors for the treatment of hepatocellular carcinoma;Berretta;Front Pharmacol,2016
2. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008
3. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial;Bruix;Lancet,2017
4. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial;Kudo;Lancet,2018
5. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma;Abou-Alfa;N Engl J Med,2018
Cited by 160 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Underlying mechanisms and management strategies for regorafenib-induced toxicity in hepatocellular carcinoma;Expert Opinion on Drug Metabolism & Toxicology;2024-09-03
2. Derivatives of D(−) glutamine-based MMP-2 inhibitors as an effective remedy for the management of chronic myeloid leukemia-Part-I: Synthesis, biological screening and in silico binding interaction analysis;European Journal of Medicinal Chemistry;2024-08
3. Machine learning models to predict ligand binding affinity for the orexin 1 receptor;Artificial Intelligence Chemistry;2024-06
4. Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials;Clinical Pharmacology & Therapeutics;2024-05-27
5. Effects of Short-Term Lenvatinib Administration Prior to Transarterial Chemoembolization for Hepatocellular Carcinoma;Cancers;2024-04-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3